News & Events
Press Releases
April 1, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases
March 16, 2026
Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer
Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry
March 12, 2026
Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum
WALTHAM, Mass.–Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Jonathan Violin, Ph.D., President…
February 18, 2026
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
Lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease